BR112013026327A2 - inibidores da parp para o tratamento de neuropatia periférica induzida por quimioterapia - Google Patents

inibidores da parp para o tratamento de neuropatia periférica induzida por quimioterapia

Info

Publication number
BR112013026327A2
BR112013026327A2 BR112013026327A BR112013026327A BR112013026327A2 BR 112013026327 A2 BR112013026327 A2 BR 112013026327A2 BR 112013026327 A BR112013026327 A BR 112013026327A BR 112013026327 A BR112013026327 A BR 112013026327A BR 112013026327 A2 BR112013026327 A2 BR 112013026327A2
Authority
BR
Brazil
Prior art keywords
treatment
chemotherapy
peripheral neuropathy
parp inhibitors
induced peripheral
Prior art date
Application number
BR112013026327A
Other languages
English (en)
Inventor
R Shoemaker Alexander
Brederson Jill-Desiree
E Browman Kaitlin
K Joshi Shailen
D Penning Thomas
Louis Giranda Vicent
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45976523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013026327(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112013026327A2 publication Critical patent/BR112013026327A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

inibidores da parp para o tratamento de neuropatia periférica induzida por quimioterapia a presente invenção diz respeito ao método para tratar neuropatia induzida por quimioterapia em um indivíduo que necessita desse tratamento com o uso de um inibidor da poli(adp-ribose)polimerase (parp).
BR112013026327A 2011-04-11 2012-04-09 inibidores da parp para o tratamento de neuropatia periférica induzida por quimioterapia BR112013026327A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473970P 2011-04-11 2011-04-11
US201161476616P 2011-04-18 2011-04-18
PCT/US2012/032724 WO2012141990A1 (en) 2011-04-11 2012-04-09 Parp inhibitors for the treatment of cipn

Publications (1)

Publication Number Publication Date
BR112013026327A2 true BR112013026327A2 (pt) 2019-09-24

Family

ID=45976523

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013026327A BR112013026327A2 (pt) 2011-04-11 2012-04-09 inibidores da parp para o tratamento de neuropatia periférica induzida por quimioterapia

Country Status (17)

Country Link
US (2) US20120258180A1 (pt)
EP (1) EP2696870A1 (pt)
JP (1) JP2014510787A (pt)
CN (1) CN103687597A (pt)
AR (1) AR085976A1 (pt)
AU (1) AU2012243132A1 (pt)
BR (1) BR112013026327A2 (pt)
CA (1) CA2832817A1 (pt)
CL (1) CL2013002908A1 (pt)
DO (1) DOP2013000236A (pt)
IL (1) IL228719A0 (pt)
MX (1) MX2013011932A (pt)
NZ (1) NZ616227A (pt)
RU (1) RU2013150102A (pt)
SG (2) SG194138A1 (pt)
TW (1) TW201244714A (pt)
WO (1) WO2012141990A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
US20160151339A1 (en) * 2013-03-21 2016-06-02 Hossein A. Ghanbari Treatment for Chemotherapy-Induced Peripheral Neuropathy
US20140287021A1 (en) * 2013-03-21 2014-09-25 Panacea Pharmaceuticals Treatment of chemotherapy-induced peripheral neuropathy
DK3594343T3 (da) 2015-07-23 2021-06-28 Inst Curie Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018245892B2 (en) * 2017-03-31 2022-02-24 Toray Industries, Inc. Therapeutic or prophylactic agent for peripheral neuropathies
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
JP2022512927A (ja) * 2018-11-08 2022-02-07 イン８バイオ、インコーポレイテッド 癌を処置するための組成物および方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4216980B1 (en) * 2020-09-22 2024-04-10 Anilur Pharma, S.L. C-phycocyanin for use in the treatment and/or prevention of peripheral neuropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078711A2 (en) * 2005-01-19 2006-07-27 Mgi Gp, Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
CN101370497B (zh) 2006-01-17 2010-11-17 雅培制药有限公司 包含parp抑制剂和细胞毒性剂的联合产品及用途
RS53196B (en) 2006-12-28 2014-06-30 Abbvie Inc. INHIBITORI POLI (ADP-RIBOZA) POLIMERAZE
KR101596526B1 (ko) * 2007-10-03 2016-02-22 에이자이 아이엔씨. Ｐａｒｐ 억제제 화합물, 조성물 및 사용 방법
MX2010003771A (es) * 2007-10-12 2010-04-21 Abbott Lab Forma cristalina 2 - de 2 ((r)-2-metilpirrolidin-2-il)-1h-benzimid azol-4-carboxamida.

Also Published As

Publication number Publication date
CN103687597A (zh) 2014-03-26
CA2832817A1 (en) 2012-10-18
SG194138A1 (en) 2013-11-29
WO2012141990A1 (en) 2012-10-18
CL2013002908A1 (es) 2013-12-06
AR085976A1 (es) 2013-11-06
EP2696870A1 (en) 2014-02-19
IL228719A0 (en) 2013-12-31
US20120258180A1 (en) 2012-10-11
DOP2013000236A (es) 2014-01-15
AU2012243132A1 (en) 2013-10-24
RU2013150102A (ru) 2015-05-20
NZ616227A (en) 2016-01-29
JP2014510787A (ja) 2014-05-01
MX2013011932A (es) 2013-11-01
US20140093585A1 (en) 2014-04-03
SG2014014294A (en) 2014-06-27
TW201244714A (en) 2012-11-16

Similar Documents

Publication Publication Date Title
BR112013026327A2 (pt) inibidores da parp para o tratamento de neuropatia periférica induzida por quimioterapia
AR121312A2 (es) AGENTES DE ARNi, COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR ENFERMEDADES ASOCIADAS CON TRANSTIRETINA (TTR)
BR112019003914A2 (pt) inibidores de processos metabólicos celulares
DOP2015000098A (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
CL2013003638A1 (es) Compuestos inhibidores de metaloenzimas; composición que comprende dichos compuestos; uso de la composición para tratar o prevenir una enfermedad asociada a metaloenzimas en plantas; uso para inhibir metaloenzimas en microorganismos y tratar un trastorno fúngico en plantas.
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112017018234A2 (pt) inibidores de pd-1 / pd-l1 para o tratamento de câncer
BR112014010631A2 (pt) inibidores de pak para o tratamento da síndrome do x frágil
DOP2014000107A (es) AGENTES DE iARN, COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR ENFERMEDADES ASOCIADAS CON TRANSTIRETINA (TTR)
BR112013032215A2 (pt) método e sistema para processamento de consultas de saldo de contas financeiras
CL2016000042A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.
BR112014004937A2 (pt) método para tratar e/ou prevenir um câncer dependente de ligante de ahr natural e inibidor de ahr
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
BR112016026544A2 (pt) métodos para inibir a necroptose
BR112013017499A2 (pt) combinação de sirosingopina e inibidores mitocondriais para o tratamento de câncer e imunossupressão
PE20151494A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
BR112014027995A2 (pt) uso de seaprose para remover biopelícula bacteriana
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
ECSP14027393A (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides
GT201400038A (es) Composiciones y métodos para tratar el cáncer usando el inhibidor de p13kbeta y el inhibidor de la vía de mapk, incluidos los inhibidores de mek y raf
CL2011002569A1 (es) Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r.
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
BR112013018336A2 (pt) famílias de inibidores de incrustação com diferentes perfis de absorção e suas aplicações em campo petrolífero

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.